China Plasmid Dna Manufacturing Market Size & Outlook
China plasmid dna manufacturing market, 2018-2030 (US$M)
Related Markets
China plasmid dna manufacturing market highlights
- The China plasmid dna manufacturing market generated a revenue of USD 114.4 million in 2023 and is expected to reach USD 431.3 million by 2030.
- The China market is expected to grow at a CAGR of 20.9% from 2024 to 2030.
- In terms of segment, gmp grade was the largest revenue generating grade in 2023.
- GMP Grade is the most lucrative grade segment registering the fastest growth during the forecast period.
Plasmid dna manufacturing market data book summary
| Market revenue in 2023 | USD 114.4 million |
| Market revenue in 2030 | USD 431.3 million |
| Growth rate | 20.9% (CAGR from 2023 to 2030) |
| Largest segment | Gmp grade |
| Fastest growing segment | GMP Grade |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | R&D Grade, GMP Grade |
| Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
Other key industry trends
- In terms of revenue, China accounted for 6.3% of the global plasmid dna manufacturing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China plasmid dna manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 390.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Manufacturing Market Scope
Plasmid DNA Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China plasmid dna manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 86.1% in 2023. Horizon Databook has segmented the China plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
The China plasmid DNA manufacturing market is expected to grow at a lucrative rate owing to advancements in the regulatory framework for cell-based research activities in the country. Furthermore, several biopharmaceutical companies are shifting their focus toward these advanced therapies with increasing investment in the field of cell & gene therapy.
This production facility has the ability to produce viral and non-viral forms of vectors, including AAV, plasmids, cell lines, lentivirus, and mRNA. This investment is expected to drive plasmid DNA manufacturing market in China.
For instance, in January 2021, vaccine Biopharmaceuticals Suzhou Co., Ltd and INOVIO signed licensing agreement to commercialize INO-800—a COVID-19 DNA vaccine—in greater China area, including Taiwan, Hong Kong, Macao, and Mainland China.
Reasons to subscribe to China plasmid dna manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China plasmid dna manufacturing market databook
-
Our clientele includes a mix of plasmid dna manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into China plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China plasmid dna manufacturing market size, by grade, 2018-2030 (US$M)
China Plasmid DNA Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
